Phase 2 trial on Semaglutide

Phase 2 trial on Semaglutide

From Hormone Insight by FWA

October 20, 2024 · 4 min

About this episode

This episode discusses the effectiveness of semaglutide in managing type 2 diabetes based on a recent study.

This episode explores the potential of semaglutide, a once-weekly GLP-1 analog, in managing type 2 diabetes. We examines a groundbreaking study published in Diabetes Care which found that semaglutide effectively reduces HbA1c levels and promotes weight loss in patients. The episode breaks down the study's findings, highlighting the dose-dependent effects of semaglutide and strategies for managing potential side effects. Tune in for insights into this promising new treatment option. Nauck, M.A., Petrie, J.R., Sesti, G. et al., 2016. A Phase 2, Randomized, Dose-Finding Study of the Novel Once-Weekly Human GLP-1 Analog, Semaglutide, Compared With Placebo and Open-Label Liraglutide in Patients With Type 2 Diabetes. Diabetes Care, 39(2), pp.231–241. https://doi.org/10.2337/dc15-0165

Topics covered

  • semaglutide
  • type 2 diabetes
  • GLP-1 analogs
  • HbA1c reduction
  • weight loss
  • clinical trials
  • side effects management

Keywords

  • semaglutide
  • type 2 diabetes
  • HbA1c
  • weight loss
  • GLP-1
  • clinical study
  • side effects

Mentioned in this episode

Organizations: Diabetes Care

Products: semaglutide, GLP-1 analog, liraglutide

Books & works: A Phase 2, Randomized, Dose-Finding Study of the Novel Once-Weekly Human GLP-1 Analog, Semaglutide, Compared With Placebo and Open-Label Liraglutide in Patients With Type 2 Diabetes

More episodes of Hormone Insight

Explore listener stats, chart rankings, contacts and more on the Hormone Insight podcast page.